GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bausch & Lomb Corp (TSX:BLCO) » Definitions » Gross Margin %

Bausch & Lomb (TSX:BLCO) Gross Margin %

: 60.70% (As of Dec. 2023)
View and export this data going back to 2022. Start your Free Trial

Gross Margin % is calculated as gross profit divided by its revenue. Bausch & Lomb's Gross Profit for the three months ended in Dec. 2023 was C$955 Mil. Bausch & Lomb's Revenue for the three months ended in Dec. 2023 was C$1,574 Mil. Therefore, Bausch & Lomb's Gross Margin % for the quarter that ended in Dec. 2023 was 60.70%.

Warning Sign:

Bausch & Lomb Corp gross margin has been in long-term decline. The average rate of decline per year is -1.6%.


The historical rank and industry rank for Bausch & Lomb's Gross Margin % or its related term are showing as below:

TSX:BLCO' s Gross Margin % Range Over the Past 10 Years
Min: 59.69   Med: 61.69   Max: 64.88
Current: 60.4


During the past 6 years, the highest Gross Margin % of Bausch & Lomb was 64.88%. The lowest was 59.69%. And the median was 61.69%.

TSX:BLCO's Gross Margin % is ranked better than
61.28% of 798 companies
in the Medical Devices & Instruments industry
Industry Median: 53.54 vs TSX:BLCO: 60.40

Bausch & Lomb had a gross margin of 60.70% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Bausch & Lomb was -1.60% per year.


Bausch & Lomb Gross Margin % Historical Data

The historical data trend for Bausch & Lomb's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch & Lomb Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Premium Member Only 64.88 62.34 61.04 59.69 60.40

Bausch & Lomb Quarterly Data
Dec18 Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57.83 60.04 59.71 61.07 60.70

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Bausch & Lomb's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bausch & Lomb Gross Margin % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Bausch & Lomb's Gross Margin % falls into.



Bausch & Lomb Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Bausch & Lomb's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=3359.4 / 5562.274
=(Revenue - Cost of Goods Sold) / Revenue
=(5562.274 - 2202.908) / 5562.274
=60.40 %

Bausch & Lomb's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=955.2 / 1573.697
=(Revenue - Cost of Goods Sold) / Revenue
=(1573.697 - 618.478) / 1573.697
=60.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Bausch & Lomb  (TSX:BLCO) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Bausch & Lomb had a gross margin of 60.70% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Bausch & Lomb Gross Margin % Related Terms

Thank you for viewing the detailed overview of Bausch & Lomb's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bausch & Lomb (TSX:BLCO) Business Description

Traded in Other Exchanges
Address
520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4
Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.